Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Zonisamide reduces tremor scores in patients with essential tremor

March 4, 2009

Taisho scientists present new antidepressive NMU2 ligands

March 4, 2009

Intellect Neurosciences' AD candidate Oxigon reported to have copper-binding properties

March 4, 2009

Marinus presents successful results from phase II ganaxolone trial

March 3, 2009

Endo licenses axomadol and returns rights to Transdur-sufentanil

March 3, 2009

Astellas and XenoPort announce results from phase II ASP-8825/XP-13512 trial

March 3, 2009

AstraZeneca receives FDA complete response letter for Seroquel XR sNDA

March 2, 2009

Somaxon receives FDA complete response letter for Silenor

March 2, 2009

New venlafaxine prodrugs for depression imparted by Solvay

March 2, 2009

Eisai and Teikoku Seiyaku sign option and license agreement for donepezil

Feb. 27, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...